KAINOS MEDICINE, INC. Logo

KAINOS MEDICINE, INC.

Develops small molecule drugs for neurodegenerative diseases, cancers, and infectious diseases.

284620 | KO

Overview

Corporate Details

ISIN(s):
KR7284620002
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 대왕판교로 700 코리아바이오파크 제3층 제에이-301호 일부, 성남시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Kainos Medicine, Inc. is a clinical-stage research and development company specializing in the discovery of innovative medicines. The firm's primary focus is on developing novel small molecule therapeutics to address unmet medical needs in neurodegenerative disorders, cancers, and infectious diseases. Its drug pipeline includes candidates for the treatment of conditions such as Parkinson's disease, multiple system atrophy (MSA), and AIDS. The company advances its portfolio through both independent research and strategic collaborations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 00:00
Legal Proceedings Report
[기재정정]투자판단관련주요경영사항(임상시험계획변경승인신청) (다계통 위축증(MSA) 치료신약 KM-819의 임상 2상 …
Korean 26.9 KB
2025-09-05 00:00
Quarterly Report
[기재정정]분기보고서 (2025.03)
Korean 1.3 MB
2025-09-05 00:00
Interim Report
[기재정정]반기보고서 (2025.06)
Korean 1.4 MB
2025-09-05 00:00
Regulatory News Service
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내)
Korean 3.2 KB
2025-09-03 00:00
Earnings Release
[기재정정]반기또는분기매출액미달사실발생
Korean 14.3 KB
2025-09-01 00:00
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
Korean 13.2 KB
2025-08-18 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 대상결정 기한 안내)
Korean 3.0 KB
2025-08-18 00:00
Audit Report / Information
[기재정정]반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 16.6 KB
2025-08-18 00:00
Regulatory News Service
불성실공시법인지정 (공시변경)
Korean 5.6 KB
2025-08-14 00:00
Delisting Announcement
주권매매거래정지 (상장적격성 실질심사 대상 (사유발생))
Korean 4.6 KB
2025-08-14 00:00
Earnings Release
반기또는분기매출액미달사실발생
Korean 9.4 KB
2025-08-14 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 관련)
Korean 2.9 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.8 MB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 12.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB

Automate Your Workflow. Get a real-time feed of all KAINOS MEDICINE, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KAINOS MEDICINE, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KAINOS MEDICINE, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

VALIRX PLC Logo
Advancing oncology & women's health therapeutics and offering preclinical research services.
United Kingdom
VAL
VALUE GOLF Inc. Logo
A golf services hub offering reservations, solo player bookings, e-commerce, lessons, and tours.
Japan
3931
Value HR Co., Ltd. Logo
Offers a health management platform and consulting for corporate health insurance societies in Japan.
Japan
6078
Global OTA for curated tours & experiences, focusing on travel to and from Japan.
Japan
7048
A South Korean travel company offering global tour packages, flights, hotels, and corporate travel.
South Korea
094850
Virax Biolabs Group Ltd Logo
Specializes in T-cell immunity tests and diagnostics for profiling viral disease responses.
United States of America
VRAX
VisionSys AI Inc Logo
Develops AI-powered brain-computer interfaces for the healthcare and biotech sectors.
United States of America
VSA
Vivesto Logo
Develops and licenses novel cancer therapies for humans and animals using proprietary drug delivery.
Sweden
VIVE
Vor Biopharma Inc. Logo
Clinical-stage biotech developing next-gen medicines that target the root cause of autoimmune disease.
United States of America
VOR
Voronoi, Inc. Logo
Develops selective kinase inhibitors and targeted protein degraders for precision oncology.
South Korea
310210

Talk to a Data Expert

Have a question? We'll get back to you promptly.